Genetics of Coronary Artery Disease

Circulation Research

Volumn 118, Issue 4, 2016, Pages 564-578

  McPherson, Ruth ^a   Tybjaerg Hansen, Anne ^b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b Rigshospitalet   (Denmark)

Author keywords

coronary artery disease; genetics; genome wide association study; Mendelian randomization analysis; polymorphism, single nucleotide

Indexed keywords

GENOMIC DNA; LOW DENSITY LIPOPROTEIN; GENETIC MARKER;

ALLELE; ARTICLE; CLINICAL MEDICINE; CODING; CORONARY ARTERY DISEASE; DNA MICROARRAY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; GENOME; GENOTYPE; HAPLOTYPE MAP; HERITABILITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; GENETIC ASSOCIATION STUDY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84959041610     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306566     Document Type: Article

References (143)

1. Vinkhuyzen AA, Wray NR, Yang J, Goddard ME, Visscher PM., Estimation and partition of heritability in human populations using whole-genome analysis methods. Annu Rev Genet 2013 47 75 95. doi: 10.1146/annurev-genet-111212-133258.
2. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, Levy D, Murabito JM, Wang TJ, Wilson PW, O'Donnell CJ., Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004 291 2204 2211. doi: 10.1001/jama.291.18.2204.
3. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire U., Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med 2002 252 247 254
4. Schunkert H, König IR, Kathiresan S, Cardiogenics; CARDIoGRAM Consortium Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011 43 333 338. doi: 10.1038/ng.784.
5. McPherson R., A gene-centric approach to elucidating cardiovascular risk. Circ Cardiovasc Genet 2009 2 3 6. doi: 10.1161/CIRCGENETICS.109.848986.
6. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC., A common allele on chromosome 9 associated with coronary heart disease. Science 2007 316 1488 1491. doi: 10.1126/science.1142447.
7. Helgadottir A, Thorleifsson G, Manolescu A, A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007 316 1491 1493. doi: 10.1126/science.1142842.
8. Samani NJ, Erdmann J, Hall AS, WTCCC and the Cardiogenics Consortium Genomewide association analysis of coronary artery disease. N Engl J Med 2007 357 443 453. doi: 10.1056/NEJMoa072366.
9. Dandona S, Stewart AF, Chen L, Williams K, So D, O'Brien E, Glover C, Lemay M, Assogba O, Vo L, Wang YQ, Labinaz M, Wells GA, McPherson R, Roberts R., Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol 2010 56 479 486. doi: 10.1016/j.jacc.2009.10.092.
10. Chan K, Patel RS, Newcombe P, Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol 2013 61 957 970. doi: 10.1016/j.jacc.2012.10.051.
11. Ye S, Willeit J, Kronenberg F, Xu Q, Kiechl S., Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol 2008 52 378 384. doi: 10.1016/j.jacc.2007.11.087.
12. Smith JG, Melander O, Lövkvist H, Hedblad B, Engström G, Nilsson P, Carlson J, Berglund G, Norrving B, Lindgren A., Common genetic variants on chromosome 9p21 confers risk of ischemic stroke: a large-scale genetic association study. Circ Cardiovasc Genet 2009 2 159 164. doi: 10.1161/CIRCGENETICS.108.835173.
13. Anderson CD, Biffi A, Rost NS, Cortellini L, Furie KL, Rosand J., Chromosome 9p21 in ischemic stroke: population structure and meta-analysis. Stroke 2010 41 1123 1131. doi: 10.1161/STROKEAHA.110.580589.
14. Cluett C, McDermott MM, Guralnik J, Ferrucci L, Bandinelli S, Miljkovic I, Zmuda JM, Li R, Tranah G, Harris T, Rice N, Henley W, Frayling TM, Murray A, Melzer D., The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people. Circ Cardiovasc Genet 2009 2 347 353. doi: 10.1161/CIRCGENETICS.108.825935.
15. Bown MJ, Braund PS, Thompson J, London NJ, Samani NJ, Sayers RD., Association between the coronary artery disease risk locus on chromosome 9p21.3 and abdominal aortic aneurysm. Circ Cardiovasc Genet 2008 1 39 42. doi: 10.1161/CIRCGENETICS.108.789727.
16. Helgadottir A, Thorleifsson G, Magnusson KP, The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008 40 217 224. doi: 10.1038/ng.72.
17. Musunuru K, Post WS, Herzog W, Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. Circ Cardiovasc Genet 2010 3 445 453. doi: 10.1161/CIRCGENETICS.109.923508.
18. Fan M, Dandona S, McPherson R, Allayee H, Hazen SL, Wells GA, Roberts R, Stewart AF., Two chromosome 9p21 haplotype blocks distinguish between coronary artery disease and myocardial infarction risk. Circ Cardiovasc Genet 2013 6 372 380. doi: 10.1161/CIRCGENETICS.113.000104.
19. Ernst FD, Uhr K, Teumer A, Fanghänel J, Schulz S, Noack B, Gonzales J, Reichert S, Eickholz P, Holtfreter B, Meisel P, Linden GJ, Homuth G, Kocher T., Replication of the association of chromosomal region 9p21.3 with generalized aggressive periodontitis (gAgP) using an independent case-control cohort. BMC Med Genet 2010 11 119. doi: 10.1186/1471-2350-11-119.
20. Schaefer AS, Richter GM, Groessner-Schreiber B, Noack B, Nothnagel M, El Mokhtari NE, Loos BG, Jepsen S, Schreiber S., Identification of a shared genetic susceptibility locus for coronary heart disease and periodontitis. PLoS Genet 2009 5 e1000378. doi: 10.1371/journal.pgen.1000378.
21. Kathiresan S, Voight BF, Purcell S, Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009 41 334 41. doi: 10.1038/ng.327.
22. Peden JF, Hopewell JC, Saleheen D, A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011 43 339 44. doi: 10.1038/ng.782.
23. Deloukas P, Kanoni S, Willenborg C, Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013 45 25 33. doi: 10.1038/ng.2480.
24. Trégouët DA, König IR, Erdmann J, Wellcome Trust Case Control Consortium; Cardiogenics Consortium Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009 41 283 285. doi: 10.1038/ng.314.
25. Nikpay M, Goel A, Won HH, CARDIoGRAMplusC4D Consortium A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015 47 1121 1130. doi: 10.1038/ng.3396.
26. Yang J, Lee SH, Goddard ME, Visscher PM., GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 2011 88 76 82. doi: 10.1016/j.ajhg.2010.11.011.
27. Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, Heath AC, Martin NG, Montgomery GW, Weedon MN, Loos RJ, Frayling TM, McCarthy MI, Hirschhorn JN, Goddard ME, Visscher PM, Genetic Investigation of ANthropometric Traits (GIANT) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet 2012 44 369 375, S1-S3. doi: 10.1038/ng.2213.
28. Maurano MT, Humbert R, Rynes E, Systematic localization of common disease-associated variation in regulatory DNA. Science 2012 337 1190 1195. doi: 10.1126/science.1222794.
29. Won HH, Natarajan P, Dobbyn A, Jordan DM, Roussos P, Lage K, Raychaudhuri S, Stahl E, Do R., Disproportionate contributions of select genomic compartments and cell types to genetic risk for coronary artery disease. PLoS Genet 2015 11 e1005622. doi: 10.1371/journal.pgen.1005622.
30. Lonjou C, Zhang W, Collins A, Tapper WJ, Elahi E, Maniatis N, Morton NE., Linkage disequilibrium in human populations. Proc Natl Acad Sci USA 2003 100 6069 6074. doi: 10.1073/pnas.1031521100.
31. Campbell MC, Tishkoff SA., African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008 9 403 433. doi: 10.1146/annurev.genom.9.081307.164258.
32. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, Frazer KA, Cox DR., Whole-genome patterns of common DNA variation in three human populations. Science 2005 307 1072 1079. doi: 10.1126/science.1105436.
33. Edwards SL, Beesley J, French JD, Dunning AM., Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet 2013 93 779 797. doi: 10.1016/j.ajhg.2013.10.012.
34. Marigorta UM, Navarro A., High trans-ethnic replicability of GWAS results implies common causal variants. PLoS Genet 2013 9 e1003566. doi: 10.1371/journal.pgen.1003566.
35. Franceschini N, Carty C, Bůzková P, Association of genetic variants and incident coronary heart disease in multiethnic cohorts: the PAGE study. Circ Cardiovasc Genet 2011 4 661 672. doi: 10.1161/CIRCGENETICS.111.960096.
36. Kral BG, Mathias RA, Suktitipat B, Ruczinski I, Vaidya D, Yanek LR, Quyyumi AA, Patel RS, Zafari AM, Vaccarino V, Hauser ER, Kraus WE, Becker LC, Becker DM., A common variant in the CDKN2B gene on chromosome 9p21 protects against coronary artery disease in Americans of African ancestry. J Hum Genet 2011 56 224 229. doi: 10.1038/jhg.2010.171.
37. Lettre G, Palmer CD, Young T, Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet 2011 7 e1001300. doi: 10.1371/journal.pgen.1001300.
38. Carlson CS, Matise TC, North KE, PAGE Consortium Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study. PLoS Biol 2013 11 e1001661. doi: 10.1371/journal.pbio.1001661.
39. Wojczynski MK, Li M, Bielak LF, Genetics of coronary artery calcification among African Americans, a meta-analysis. BMC Med Genet 2013 14 75. doi: 10.1186/1471-2350-14-75.
40. Evans DM, Davey Smith G., Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet 2015 16 327 350. doi: 10.1146/annurev-genom-090314-050016.
41. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG., Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009 301 2331 2339. doi: 10.1001/jama.2009.801.
42. Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J., Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009 302 412 423. doi: 10.1001/jama.2009.1063.
43. Clarke R, Peden JF, Hopewell JC, PROCARDIS Consortium Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009 361 2518 2528. doi: 10.1056/NEJMoa0902604.
44. Thanassoulis G, Campbell CY, Owens DS, CHARGE Extracoronary Calcium Working Group Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013 368 503 512. doi: 10.1056/NEJMoa1109034.
45. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG., Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014 63 470 477. doi: 10.1016/j.jacc.2013.09.038.
46. Koschinsky ML, Boffa MB., Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum. Endocrinol Metab Clin North Am 2014 43 949 962. doi: 10.1016/j.ecl.2014.08.002.
47. Abifadel M, Varret M, Rabès JP, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 34 154 156. doi: 10.1038/ng1161.
48. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006 354 1264 1272. doi: 10.1056/NEJMoa054013.
49. Cannon CP, Blazing MA, Giugliano RP, IMPROVE-IT Investigators Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 372 2387 2397. doi: 10.1056/NEJMoa1410489.
50. Stitziel NO, Won HH, Morrison AC, Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014 371 2072 2082. doi: 10.1056/NEJMoa1405386.
51. Lauridsen BK, Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A., Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J 2015 36 1601 1608. doi: 10.1093/eurheartj/ehv108.
52. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD., Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015 65 1552 1561. doi: 10.1016/j.jacc.2015.02.020.
53. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A., PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010 55 2833 2842. doi: 10.1016/j.jacc.2010.02.044.
54. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM., Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012 60 2631 2639. doi: 10.1016/j.jacc.2012.09.017.
55. Nordestgaard BG, Varbo A., Triglycerides and cardiovascular disease. Lancet 2014 384 626 635. doi: 10.1016/S0140-6736(14)61177-6.
56. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A., Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997 96 1737 1744
57. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, Steffensen R, Schnohr P, Nordestgaard BG., A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997 99 1606 1613. doi: 10.1172/JCI119323.
58. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG., Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999 99 2901 2907
59. Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG., Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study. Clin Chem 2014 60 737 746. doi: 10.1373/clinchem.2013.219881.
60. Crosby J, Peloso GM, Auer PL, TG and HDL Working Group of the Exome Sequencing Project; National Heart, Lung, and Blood Institute Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014 371 22 231. doi: 10.1056/NEJMoa1307095.
61. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A., Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014 371 32 41. doi: 10.1056/NEJMoa1308027.
62. Do R, Stitziel NO, Won HH, NHLBI Exome Sequencing Project Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015 518 102 106. doi: 10.1038/nature13917.
63. Sarwar N, Sandhu MS, Ricketts SL, Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010 375 1634 1639. doi: 10.1016/S0140-6736(10)60545-4.
64. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A., Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013 34 1826 1833. doi: 10.1093/eurheartj/ehs431.
65. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG., Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013 61 427 436. doi: 10.1016/j.jacc.2012.08.1026.
66. Do R, Willer CJ, Schmidt EM, Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013 45 1345 1352. doi: 10.1038/ng.2795.
67. Haase CL, Tybjærg-Hansen A, Grande P, Frikke-Schmidt R., Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2010 95 E500 E510. doi: 10.1210/jc.2010-0450.
68. Haase CL, Frikke-Schmidt R, Nordestgaard BG, Kateifides AK, Kardassis D, Nielsen LB, Andersen CB, Køber L, Johnsen AH, Grande P, Zannis VI, Tybjaerg-Hansen A., Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. J Intern Med 2011 270 136 146. doi: 10.1111/j.1365-2796.2011.02381.x.
69. Haase CL, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A., Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS Genet 2012 8 e1003063. doi: 10.1371/journal.pgen.1003063.
70. Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JH, Petersen W, Dullaart RP, Stroes ES, Zwinderman AH, de Groot E, Hayden MR, Kuivenhoven JA, Kastelein JJ., A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004 44 1429 1435. doi: 10.1016/j.jacc.2004.06.070.
71. Hazenberg AJ, Dikkers FG, Hawkins PN, Bijzet J, Rowczenio D, Gilbertson J, Posthumus MD, Leijsma MK, Hazenberg BP., Laryngeal presentation of systemic apolipoprotein A-I-derived amyloidosis. Laryngoscope 2009 119 608 615. doi: 10.1002/lary.20106.
72. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG., Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008 359 1897 1908. doi: 10.1056/NEJMoa0707402.
73. Schick UM, Auer PL, Bis JC, Cohorts for Heart and Aging Research in Genomic Epidemiology; National Heart, Lung, and Blood Institute GO Exome Sequencing Project Association of exome sequences with plasma C-reactive protein levels in >9000 participants. Hum Mol Genet 2015 24 559 571. doi: 10.1093/hmg/ddu450.
74. 2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010 122 2183 2200. doi: 10.1161/CIRCULATIONAHA.110.936393.
75. Thompson A, Gao P, Orfei L, Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010 375 1536 1544. doi: 10.1016/S0140-6736(10)60319-4.
76. Casas JP, Ninio E, Panayiotou A, PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010 121 2284 2293. doi: 10.1161/CIRCULATIONAHA.109.923383.
77. Holmes MV, Simon T, Exeter HJ, Secretory phospholipase A(2)-IIA and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol 2013 62 1966 1976. doi: 10.1016/j.jacc.2013.06.044.
78. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE, VISTA-16 Investigators Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014 311 252 262. doi: 10.1001/jama.2013.282836.
79. White HD, Held C, Stewart R, Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014 370 1702 1711. doi: 10.1056/NEJMoa1315878.
80. Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjærg-Hansen A., Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol 2012 60 2041 2048. doi: 10.1016/j.jacc.2012.07.045.
81. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J., Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008 299 2777 2788. doi: 10.1001/jama.299.23.2777.
82. Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI., Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009 2 26 33. doi: 10.1161/CIRCGENETICS.108.817304.
83. Voight BF, Peloso GM, Orho-Melander M, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012 380 572 580. doi: 10.1016/S0140-6736(12)60312-2.
84. Inazu A, Koizumi J, Kajinami K, Kiyohar T, Chichibu K, Mabuchi H., Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis 1999 145 405 413
85. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ., The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998 338 86 93. doi: 10.1056/NEJM199801083380203.
86. Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH, van der Graaf Y, Bots ML, Doevendans PA., CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008 29 2792 2799. doi: 10.1093/eurheartj/ehn465.
87. Shah S, Casas JP, Drenos F, Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis. Circ Cardiovasc Genet 2013 6 63 72. doi: 10.1161/CIRCGENETICS.112.963140.
88. Brautbar A, Ballantyne CM, Lawson K, Nambi V, Chambless L, Folsom AR, Willerson JT, Boerwinkle E., Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet 2009 2 279 285. doi: 10.1161/CIRCGENETICS.108.817338.
89. Davies RW, Dandona S, Stewart AF, Chen L, Ellis SG, Tang WH, Hazen SL, Roberts R, McPherson R, Wells GA., Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet 2010 3 468 474. doi: 10.1161/CIRCGENETICS.110.946269.
90. Ripatti S, Tikkanen E, Orho-Melander M, A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 2010 376 1393 1400. doi: 10.1016/S0140-6736(10)61267-6.
91. Ganna A, Magnusson PK, Pedersen NL, de Faire U, Reilly M, Arnlöv J, Sundström J, Hamsten A, Ingelsson E., Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol 2013 33 2267 2272. doi: 10.1161/ATVBAHA.113.301218.
92. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S., Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol 2013 33 2261 2266. doi: 10.1161/ATVBAHA.112.301120.
93. Mega JL, Stitziel NO, Smith JG, Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015 385 2264 2271. doi: 10.1016/S0140-6736(14)61730-X.
94. Casas JP, Cooper J, Miller GJ, Hingorani AD, Humphries SE., Investigating the genetic determinants of cardiovascular disease using candidate genes and meta-analysis of association studies. Ann Hum Genet 2006 70 145 169. doi: 10.1111/j.1469-1809.2005.00241.x.
95. Wang L, Fan C, Topol SE, Topol EJ, Wang Q., Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003 302 1578 1581. doi: 10.1126/science.1088477.
96. Weng L, Kavaslar N, Ustaszewska A, Doelle H, Schackwitz W, Hébert S, Cohen JC, McPherson R, Pennacchio LA., Lack of MEF2A mutations in coronary artery disease. J Clin Invest 2005 115 1016 1020. doi: 10.1172/JCI24186.
97. Chong JX, Buckingham KJ, Jhangiani SN, Centers for Mendelian Genomics The genetic basis of Mendelian phenotypes: discoveries, challenges, and opportunities. Am J Hum Genet 2015 97 199 215. doi: 10.1016/j.ajhg.2015.06.009.
98. Arndt AK, MacRae CA., Genetic testing in cardiovascular diseases. Curr Opin Cardiol 2014 29 235 240. doi: 10.1097/HCO.0000000000000055.
99. McPherson R, Hegele RA., Ezetimibe: rescued by randomization (clinical and Mendelian). Arterioscler Thromb Vasc Biol 2015 35 e13 e15. doi: 10.1161/ATVBAHA.114.305012.
100. Moutsianas L, Agarwala V, Fuchsberger C, Flannick J, Rivas MA, Gaulton KJ, Albers PK, McVean G, Boehnke M, Altshuler D, McCarthy MI, GoT2D Consortium The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease. PLoS Genet 2015 11 e1005165. doi: 10.1371/journal.pgen.1005165.
101. Cole CB, Nikpay M, McPherson R., Gene-environment interaction in dyslipidemia. Curr Opin Lipidol 2015 26 133 138. doi: 10.1097/MOL.0000000000000160.
102. Cole CB, Nikpay M, Lau P, Stewart AF, Davies RW, Wells GA, Dent R, McPherson R., Adiposity significantly modifies genetic risk for dyslipidemia. J Lipid Res 2014 55 2416 2422. doi: 10.1194/jlr.P052522.
103. Turner AW, Nikpay M, Silva A, Lau P, Martinuk A, Linseman TA, Soubeyrand S, McPherson R., Functional interaction between COL4A1/COL4A2 and SMAD3 risk loci for coronary artery disease. Atherosclerosis 2015 242 543 552. doi: 10.1016/j.atherosclerosis.2015.08.008.
104. Jia P, Wang L, Fanous AH, Pato CN, Edwards TL, Zhao Z, International Schizophrenia Consortium Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput Biol 2012 8 e1002587. doi: 10.1371/journal.pcbi.1002587.
105. Ghosh S, Vivar J, Nelson CP, Systems genetics analysis of genome-wide association study reveals novel associations between key biological processes and coronary artery disease. Arterioscler Thromb Vasc Biol 2015 35 1712 1722. doi: 10.1161/ATVBAHA.115.305513.
106. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005 102 15545 15550. doi: 10.1073/pnas.0506580102.
107. Wang K, Li M, Bucan M., Pathway-based approaches for analysis of genomewide association studies. Am J Hum Genet 2007 81 1278 1283. doi: 10.1086/522374.
108. Wang K, Li M, Hakonarson H., Analysing biological pathways in genome-wide association studies. Nat Rev Genet 2010 11 843 854. doi: 10.1038/nrg2884.
109. Wang L, Jia P, Wolfinger RD, Chen X, Zhao Z., Gene set analysis of genome-wide association studies: methodological issues and perspectives. Genomics 2011 98 1 8. doi: 10.1016/j.ygeno.2011.04.006.
110. Segrè AV, Groop L, Mootha VK, Daly MJ, Altshuler D, DIAGRAM Consortium; MAGIC Investigators Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 2010 6. doi: 10.1371/journal.pgen.1001058.
111. Nam D, Kim J, Kim SY, Kim S., GSA-SNP: a general approach for gene set analysis of polymorphisms. Nucleic Acids Res 2010 38 W749 W754. doi: 10.1093/nar/gkq428.
112. Zhang K, Cui S, Chang S, Zhang L, Wang J., i-GSEA4GWAS: a web server for identification of pathways/gene sets associated with traits by applying an improved gene set enrichment analysis to genome-wide association study. Nucleic Acids Res 2010 38 W90 W95. doi: 10.1093/nar/gkq324.
113. Matthews L, Gopinath G, Gillespie M, Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 2009 37 D619 D622. doi: 10.1093/nar/gkn863.
114. Björkegren JL, Kovacic JC, Dudley JT, Schadt EE., Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J Am Coll Cardiol 2015 65 830 845. doi: 10.1016/j.jacc.2014.12.033.
115. Oti M, Brunner HG., The modular nature of genetic diseases. Clin Genet 2007 71 1 11. doi: 10.1111/j.1399-0004.2006.00708.x.
116. Feldman I, Rzhetsky A, Vitkup D., Network properties of genes harboring inherited disease mutations. Proc Natl Acad Sci USA 2008 105 4323 4328. doi: 10.1073/pnas.0701722105.
117. Schmidt EF, Strittmatter SM., The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol 2007 600 1 11. doi: 10.1007/978-0-387-70956-7-1.
118. van Gils JM, Derby MC, Fernandes LR, The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol 2012 13 136 143. doi: 10.1038/ni.2205.
119. Oksala N, Pärssinen J, Seppälä I, Raitoharju E, Kholova I, Ivana K, Hernesniemi J, Lyytikäinen LP, Levula M, Mäkelä KM, Sioris T, Kähönen M, Laaksonen R, Hytönen V, Lehtimäki T., Association of neuroimmune guidance cue netrin-1 and its chemorepulsive receptor UNC5B with atherosclerotic plaque expression signatures and stability in human(s): Tampere Vascular Study (TVS). Circ Cardiovasc Genet 2013 6 579 587. doi: 10.1161/CIRCGENETICS.113.000141.
120. Wanschel A, Seibert T, Hewing B, Ramkhelawon B, Ray TD, van Gils JM, Rayner KJ, Feig JE, O'Brien ER, Fisher EA, Moore KJ., Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler Thromb Vasc Biol 2013 33 886 893. doi: 10.1161/ATVBAHA.112.300941.
121. van Gils JM, Ramkhelawon B, Fernandes L, Stewart MC, Guo L, Seibert T, Menezes GB, Cara DC, Chow C, Kinane TB, Fisher EA, Balcells M, Alvarez-Leite J, Lacy-Hulbert A, Moore KJ., Endothelial expression of guidance cues in vessel wall homeostasis dysregulation under proatherosclerotic conditions. Arterioscler Thromb Vasc Biol 2013 33 911 919. doi: 10.1161/ATVBAHA.112.301155.
122. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S., Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol 2010 6 e1001025. doi: 10.1371/journal.pcbi.1001025.
123. Esteller M., Non-coding RNAs in human disease. Nat Rev Genet 2011 12 861 874. doi: 10.1038/nrg3074.
124. Gillette TG, Hill JA., Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ Res 2015 116 1245 1253. doi: 10.1161/CIRCRESAHA.116.303630.
125. Shea J, Agarwala V, Philippakis AA, Maguire J, Banks E, Depristo M, Thomson B, Guiducci C, Onofrio RC, Kathiresan S, Gabriel S, Burtt NP, Daly MJ, Groop L, Altshuler D, Myocardial Infarction Genetics Consortium Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. Nat Genet 2011 43 801 805. doi: 10.1038/ng.871.
126. Yang J, Huang T, Petralia F, Long Q, Zhang B, Argmann C, Zhao Y, Mobbs CV, Schadt EE, Zhu J, Tu Z, GTEx Consortium Synchronized age-related gene expression changes across multiple tissues in human and the link to complex diseases. Sci Rep 2015 5 15145. doi: 10.1038/srep15145.
127. Zhang W, Gamazon ER, Zhang X, Konkashbaev A, Liu C, Szilágyi KL, Dolan ME, Cox NJ., SCAN database: facilitating integrative analyses of cytosine modification and expression QTL. Database (Oxford) 2015 1-7. doi: 10.1093/database/bav025.
128. Brown CD, Mangravite LM, Engelhardt BE., Integrative modeling of eQTLs and cis-regulatory elements suggests mechanisms underlying cell type specificity of eQTLs. PLoS Genet 2013 9 e1003649. doi: 10.1371/journal.pgen.1003649.
129. ENCODE Project Consortium A user's guide to the Encyclopedia of DNA Elements (ENCODE). PLoS Biol 2011 9 e1001046. doi: 10.1371/journal.pbio.1001046.
130. Chadwick LH., The NIH Roadmap Epigenomics Program data resource. Epigenomics 2012 4 317 324. doi: 10.2217/epi.12.18.
131. Park PJ., ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet 2009 10 669 680. doi: 10.1038/nrg2641.
132. Raychaudhuri S., Mapping rare and common causal alleles for complex human diseases. Cell 2011 147 57 69. doi: 10.1016/j.cell.2011.09.011.
133. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K., Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008 40 897 903. doi: 10.1038/ng.154.
134. Mercer TR, Edwards SL, Clark MB, Neph SJ, Wang H, Stergachis AB, John S, Sandstrom R, Li G, Sandhu KS, Ruan Y, Nielsen LK, Mattick JS, Stamatoyannopoulos JA., DNase I-hypersensitive exons colocalize with promoters and distal regulatory elements. Nat Genet 2013 45 852 859. doi: 10.1038/ng.2677.
135. Buenrostro JD, Wu B, Chang HY, Greenleaf WJ., ATAC-seq: a method for assaying chromatin accessibility genome-wide. Curr Protoc Mol Biol 2015 109 21.29.1 21.29.9. doi: 10.1002/0471142727.mb2129s109.
136. Boyle AP, Song L, Lee BK, London D, Keefe D, Birney E, Iyer VR, Crawford GE, Furey TS., High-resolution genome-wide in vivo footprinting of diverse transcription factors in human cells. Genome Res 2011 21 456 464. doi: 10.1101/gr.112656.110.
137. Musunuru K, Strong A, Frank-Kamenetsky M, From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010 466 714 719. doi: 10.1038/nature09266.
138. Strong A, Ding Q, Edmondson AC, Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest 2012 122 2807 2816. doi: 10.1172/JCI63563.
139. Sazonova O, Zhao Y, Nürnberg S, Miller C, Pjanic M, Castano VG, Kim JB, Salfati EL, Kundaje AB, Bejerano G, Assimes T, Yang X, Quertermous T., Characterization of TCF21 downstream target regions identifies a transcriptional network linking multiple independent coronary artery disease loci. PLoS Genet 2015 11 e1005202. doi: 10.1371/journal.pgen.1005202.
140. Nurnberg ST, Cheng K, Raiesdana A, Coronary artery disease associated transcription factor TCF21 regulates smooth muscle precursor cells that contribute to the fibrous cap. PLoS Genet 2015 11 e1005155. doi: 10.1371/journal.pgen.1005155.
141. Beaudoin M, Gupta RM, Won HH, Lo KS, Do R, Henderson CA, Lavoie-St-Amour C, Langlois S, Rivas D, Lehoux S, Kathiresan S, Tardif JC, Musunuru K, Lettre G., Myocardial infarction-associated SNP at 6p24 interferes with MEF2 binding and associates with PHACTR1 expression levels in human coronary arteries. Arterioscler Thromb Vasc Biol 2015 35 1472 1479. doi: 10.1161/ATVBAHA.115.305534.
142. Pu X, Xiao Q, Kiechl S, ADAMTS7 cleavage and vascular smooth muscle cell migration is affected by a coronary-artery-disease-associated variant. Am J Hum Genet 2013 92 366 374. doi: 10.1016/j.ajhg.2013.01.012.
143. Bauer RC, Tohyama J, Cui J, Cheng L, Yang J, Zhang X, Ou K, Paschos GK, Zheng XL, Parmacek MS, Rader DJ, Reilly MP., Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice. Circulation 2015 131 1202 1213. doi: 10.1161/CIRCULATIONAHA.114.012669.